Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Duchenne muscular dystrophy – diagnosis, clinical development and global research

Its impact on patients, available treatments and why early diagnosis is essential

- PMLiVE

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

- PMLiVE

GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

The decision means that eligible patients in England will be the first in the world to access the combination

- PMLiVE

FDA approves tablet formulation of BeOne’s targeted cancer drug Brukinsa

The new formulation has been authorised for all five indications covered by the original capsule version

- PMLiVE

Patient partnerships for life

It’s not about just engaging with patients, it is about co-creating with patients, making them integral at every stage

Virtual Grant Writing & Review – Engaging Your Advisors Creatively

Boost your research initiatives! Discover how to creatively manage virtual grant writing & review programs with your KOLs, identifying key topics & streamlining proposal approvals. Foster impactful collaborations. Watch

Impetus Digital

- PMLiVE

Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

These are the first clinical study results for the drug in a large population of patients with darker skin tones

- PMLiVE

UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

Approximately 125 million people worldwide are affected by some form of psoriasis

- PMLiVE

Better together – accelerating innovation and access to rare disease treatments

Advancing rare disease research through global collaborations and unified clinical trials

- PMLiVE

FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer

ROS1-positive non-small cell lung cancer accounts for approximately 2% of new NSCLC cases

- PMLiVE

NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study

The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate

- PMLiVE

Galderma shares positive two-year results for Nemluvio in atopic dermatitis

The chronic inflammatory skin disease affects more than 230 million people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links